KC
CRBU icon

KCL Capital’s Caribou Biosciences CRBU Stock Holding History

KCL Capital’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,000
Closed -$181K – 53
2021
Q4 		$181K Buy
12,000
+2,856
+31% +$55.5K 0.02% 55
2021
Q3 		$218K Buy
+9,144
New +$224K 0.01% 46

Other funds holding CRBU

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return

KCL Capital's CRBU Position: Q1 2022 in Review

KCL Capital sold out of Caribou Biosciences (CRBU) in Q1 2022, closing a stake of 12,000 shares — an estimated $181K sold.

KCL Capital first reported a position in CRBU in Q3 2021 and held it in 2 quarters. The position peaked at $218K in Q3 2021. 104 funds tracked by Wall St. Rank hold CRBU as of Q1 2022.

  • KCL Capital reported no remaining Caribou Biosciences position as of Q1 2022 after selling out during the quarter.
  • KCL Capital sold 12,000 Caribou Biosciences shares in Q1 2022, an estimated $181K.
  • KCL Capital first reported a position in Caribou Biosciences in Q3 2021 and held it in 2 quarters.
  • KCL Capital's Caribou Biosciences position peaked at $218K in Q3 2021.
  • 104 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2022.

Based on KCL Capital's 13F filing for Q1 2022, filed 16 May 2022.